https://pharmatlas.org/ 2026-04-06T11:26:33+00:00 https://pharmatlas.org/ https://pharmatlas.org/lib/exe/fetch.php?media=logo.png text/html 2026-02-15T03:07:09+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=neuro:opioids:buprenorphine&rev=1771124829&do=diff Buprenorphine (Subutex®, Suboxone®, Butrans®) Buprenorphine Brand Names Subutex®, Suboxone®, Butrans®, Sublocade® Drug Class Opioid (Partial μ-agonist) Primary Indication Opioid Use Disorder, Chronic Pain Receptor Activity Partial μ agonist; κ antagonist text/html 2026-02-15T03:03:37+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=neuro:opioids:codeine&rev=1771124617&do=diff Codeine Codeine Brand Names — (often combination products) Drug Class Opioid (Weak μ-agonist, Prodrug) Primary Indication Mild–Moderate Pain, Antitussive Relative Potency ~0.1× Morphine Mechanism Prodrug → CYP2D6 → Morphine Hypoglycemia Risk text/html 2026-02-15T02:57:42+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=neuro:opioids:fentanyl&rev=1771124262&do=diff Fentanyl (Duragesic®) Fentanyl Brand Names Duragesic®, Sublimaze®, Actiq® Drug Class Opioid (Full μ-agonist) Primary Indication Severe Pain / Anesthesia Relative Potency ~100× Morphine Histamine Release Minimal Respiratory Depression Yes (high potency) text/html 2026-02-15T02:58:55+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=neuro:opioids:hydromorphone&rev=1771124335&do=diff Hydromorphone (Dilaudid®) Hydromorphone Brand Names Dilaudid®, Exalgo® Drug Class Opioid (Full μ-agonist) Primary Indication Moderate–Severe Pain Relative Potency 4–7× Morphine Histamine Release Minimal Respiratory Depression Yes (dose-dependent) text/html 2026-02-15T03:08:50+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=neuro:opioids:methadone&rev=1771124930&do=diff Methadone (Dolophine®) Methadone Brand Names Dolophine®, Methadose® Drug Class Opioid (Full μ-agonist) Primary Indication Opioid Use Disorder, Severe Pain Receptor Activity Full μ agonist + NMDA antagonist Relative Potency Variable (nonlinear) text/html 2026-02-15T02:56:08+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=neuro:opioids:morphine&rev=1771124168&do=diff Morphine (MS Contin®) Morphine Brand Names MS Contin®, Kadian®, Roxanol® Drug Class Opioid (Full μ-agonist) Primary Indication Moderate–Severe Pain Relative Potency 1× (Reference Standard) Histamine Release Yes Respiratory Depression text/html 2026-02-15T03:00:04+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=neuro:opioids:naloxone&rev=1771124404&do=diff Naloxone (Narcan®) Naloxone Brand Names Narcan®, Kloxxado® Drug Class Opioid Antagonist Primary Indication Opioid Overdose Mechanism Competitive μ receptor antagonist Onset 1–2 minutes (IV) Duration 30–90 minutes Controlled Substance No FDA Approval text/html 2026-02-15T02:54:47+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=neuro:opioids:oxycodone&rev=1771124087&do=diff Oxycodone (Roxicodone®, OxyContin®) Oxycodone Brand Names Roxicodone®, OxyContin®, Percocet®, Endocet® Drug Class Opioid (Full μ-agonist) Primary Indication Moderate–Severe Pain Relative Potency ~1.5× Morphine (oral) Hypoglycemia Risk text/html 2026-02-15T02:49:23+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=neuro:opioids:start&rev=1771123763&do=diff Opioids Opioids are μ-opioid receptor agonists (or partial/mixed agonists) used for moderate to severe pain, anesthesia, and palliative care. They decrease nociceptive transmission at both spinal and supraspinal levels. ---------- Mechanism of Action text/html 2026-02-15T03:02:25+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=neuro:opioids:tramadol&rev=1771124545&do=diff Tramadol (Ultram®) Tramadol Brand Names Ultram®, ConZip® Drug Class Opioid (Weak μ-agonist, Dual Mechanism) Primary Indication Moderate Pain Relative Potency ~0.1× Morphine Mechanism Weak μ agonist + SNRI Seizure Risk Yes Serotonin Syndrome Risk